Publication Topic

Hathway J, Purdum AG, Lin VW, Cyr PL, Westin J, Jensen IS. A budget impact model of axicabtagene ciloleucel (Axi-cel) in an US population of patients with relapsed or refractory large b-cell lymphoma (RR-LBCL). Podium presentation at ISPOR 23th Annual International Meeting, Baltimore MD, 2018.

Jensen I, Zacherle E, Noone J, Blanchette C, Kay C. Estimating the life-time indirect costs of vision impairment (VI) in inherited retinal degeneration (IRD): Economic impact on education, government benefit programs, productivity and tax loss for patients and caregiver burden. Presented at AAO 2018.

Sacks NC, Cyr PL, Louie AC, Liu Y, Chiarella MT, Sharma A, Chung KC. 2018. Burden of acute myeloid leukemia among older, newly diagnosed patients: Retrospective analysis of data from the 2010-2012 Medicare limited data set. Clin Ther 40(5):692–703.e2; doi: 10.1016/j.clinthera.2018.03.012.

Schwartz KL, Simon MS, Bylsma LC, Ruterbusch JJ, Beebe-Dimmer JL, Schultz NM,  Flanders SC, Barlev A, et al. 2018. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States. Cancer 124(10):2104-2114; doi: 10.1002/cncr.31299. PMID: 29505670.

Movva N, Jani A. 2018. The value of pay-for-performance in England: An evaluation of NHS England’s Quality Outcomes Framework. Value in Healthcare Review Working Paper No. 2; University of Oxford Research Archive.

Young LY, Sacks NC, Cyr PL, Sharma A, Dahdal DN. 2017. Comparison of claims data on hospitalization rates and repeat procedures in patients receiving a bowel preparation prior to colonoscopy. Sage Open Med 5(Aug 31):2050312117727999; doi: 10.1177/205031211772799. PMID: 28894587.

Wu E, Jensen IS, Cyr PL, Kisner H. Economic model shows that guideline recommended testing of patients with early symptoms of myeloma results in improved patient outcomes and decreased hospital costs. American Society of Hematology, Atlanta GA, 2017.

Jensen IS, Wu E, Cyr PL, Gauden D. Cost-consequence of use of Fluciclovine (F 18) for the diagnosis and staging of recurring prostate cancer. ISPOR 16th Annual European Congress, Glasgow, Scotland, 2017.

Sacks NC, Liu Y, Sanyal A, DeFronzo R, Bhatt DL, Caplan, J… Cyr PL, et al. The economic burden of insulin resistance, obesity, and cardiovascular disease in Medicare beneficiaries 65 years of age and older. American Heart Association Scientific Sessions, Anaheim CA, 2017.

Berger K, Rossi G, Orlando V, Fabry P, Jensen IS, Gallacher ME, et al. Mobilizing stem cells with plerixafor in MM patients: Impact on a health care provider’s budget in Germany and Italy. 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 2017.